Research progress of T cell lymphoma: reports from 2014 international conference on T cell lymphoma in clinical treatment

VernacularTitle:T细胞淋巴瘤研究新进展:2014年国际T细胞淋巴瘤临床治疗大会报道
Author: Jun MA ; Jun ZHU ; Yuankai SHI ; Wenqi JIANG ; Huiqiang HUANG ; Lin QIU
Publication Type:Journal Article
Keywords: Lymphoma,T cell; Epigenetic; Histone; Deacetylase inhibitor
From: Journal of Leukemia & Lymphoma 2014;23(11):641-645,653
CountryChina
Language:Chinese
Abstract: The treatment status and progress in T cell lymphoma including epigenetic involved mutations that control DNA and histone methylation were reported and intensively discussed in 2014 international T cell lymphoma forum.According to the theory,treatment with HDAC inhibitor belinostat and romidepsin for peripheral T cell lymphoma (PTCL) can achieve 29 ％-38 ％ overall response rate (ORR) and 13.6 months median relief time.NK/T cell lymphoma in southeast asia is a common malignant lymphoma,15 ％-28 ％ of the NHL accounted in China and Japan for,which is significantly higher than that in the European and American countries,mainly related to EB virus widespread infection.L-asparaginase enzymes,such as SMILE and AspMetDex,can make the early cases with more than 70 ％ long-term survival rate,advanced cases with 40 ％ response rate.Some new drugs,such as pralatrexate,combined with romidepsin can be used in PTCL cases to improve the complete remission rate.